Clinical Trials
14 trialsNCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT06236425 2026-04-01
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT05639972 2026-02-27
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Rutgers, The State University of New Jersey
Phase 1/2 Recruiting
NCT05686226 2026-02-27
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Rutgers, The State University of New Jersey
Phase 2 Recruiting
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT02390739 2019-12-16
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00002702 2013-08-26
Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00019331 2013-06-20
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00899821 2012-11-09
Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer
NYU Langone Health
Phase NA Completed
NCT00937300 2011-11-23
T-cell Based Immunotherapy for Head and Neck Cancer
Herlev Hospital
Phase 1 Withdrawn